[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX347723B - Compuestos farmaceuticos para usarse en la terapia de infeccion por clostridium difficile. - Google Patents

Compuestos farmaceuticos para usarse en la terapia de infeccion por clostridium difficile.

Info

Publication number
MX347723B
MX347723B MX2014003771A MX2014003771A MX347723B MX 347723 B MX347723 B MX 347723B MX 2014003771 A MX2014003771 A MX 2014003771A MX 2014003771 A MX2014003771 A MX 2014003771A MX 347723 B MX347723 B MX 347723B
Authority
MX
Mexico
Prior art keywords
therapy
clostridium difficile
pharmaceutical compounds
difficile infection
opso2
Prior art date
Application number
MX2014003771A
Other languages
English (en)
Other versions
MX2014003771A (es
Inventor
Castagner Bastien
Leroux Jean-Christophe
Ivarsson Mattias
Schneider Gisbert
Pratsinis Anna
Original Assignee
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47022623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347723(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eth Zuerich filed Critical Eth Zuerich
Publication of MX2014003771A publication Critical patent/MX2014003771A/es
Publication of MX347723B publication Critical patent/MX347723B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00—Esters of sulfuric acids
    • C07C305/20—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

(ver Fórmula) La invención se refiere a un compuesto descrito por la fórmula general (1), en donde cada X puede ser, independientemente OPO32-, OPSO22- o OSO3-; R1 comprende una función de solubilidad, tal como una parte de polietilenglicol y cada X puede ser, independientemente OPO32-, OPSO22- o OSO3-, y Z es una cadena de alquilo que comprende de 1 a 3 átomos de carbono y / o heteroátomos. La invención se refiere además a derivados de polisulfato o mezcla de derivados de polifosfato / sulfato de polioles cíclicos de seis miembros para su uso en la terapia de la infección por Clostrídíum difficile.
MX2014003771A 2011-09-29 2012-09-28 Compuestos farmaceuticos para usarse en la terapia de infeccion por clostridium difficile. MX347723B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11007935 2011-09-29
EP11007933 2011-09-29
PCT/EP2012/004088 WO2013045107A1 (en) 2011-09-29 2012-09-28 Pharmaceutical compounds for use in the therapy of clostridium difficile infection

Publications (2)

Publication Number Publication Date
MX2014003771A MX2014003771A (es) 2015-03-20
MX347723B true MX347723B (es) 2017-05-10

Family

ID=47022623

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003771A MX347723B (es) 2011-09-29 2012-09-28 Compuestos farmaceuticos para usarse en la terapia de infeccion por clostridium difficile.

Country Status (14)

Country Link
US (1) US9358243B2 (es)
EP (2) EP2773648B1 (es)
JP (1) JP5766884B2 (es)
CN (2) CN105949234B (es)
AU (2) AU2012314932B2 (es)
BR (1) BR112014007405B1 (es)
CA (1) CA2849426C (es)
DK (1) DK2773648T3 (es)
EA (1) EA024069B1 (es)
ES (1) ES2727633T3 (es)
IL (1) IL231698A (es)
MX (1) MX347723B (es)
PL (1) PL2773648T3 (es)
WO (1) WO2013045107A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5345532B2 (ja) * 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Ｌｃｔ中毒に対する医薬品
US11707470B2 (en) 2015-12-11 2023-07-25 Eth Zurich Inositol derivatives for use in pathological crystallization
DK3386994T3 (da) 2015-12-11 2020-01-13 Eth Zuerich 4,6-di-(o-thiophosphat)-inositol-1,2,3,5-tetra-o-sulfat mod c. difficile-infektion
AU2016368547B2 (en) * 2015-12-11 2021-11-18 ETH Zürich Inositol derivatives for use in pathological crystallization
US11028112B2 (en) 2015-12-11 2021-06-08 Eth Zurich Inositol derivatives for use in pathological crystallization
CN106474458B (zh) * 2017-01-05 2020-03-24 重庆医科大学 白介素-27在治疗艰难梭菌感染中的应用
WO2020058321A1 (en) * 2018-09-18 2020-03-26 Inositec Ag Calcium oxalate crystallization inhibitors for renal disorders
AU2018445164A1 (en) 2018-10-11 2021-04-22 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
KR20210148078A (ko) 2019-01-30 2021-12-07 사니핏 테라퓨틱스 에스.에이. 조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
EP4144742A4 (en) * 2020-04-30 2023-09-27 Shanghai Senhui Medicine Co., Ltd. INOSITOL DERIVATIVE AND ITS USE
EP4247388A1 (en) 2020-11-20 2023-09-27 Vifor (International) Ag Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
KR20230169073A (ko) 2021-01-26 2023-12-15 비포르 (인터내셔날) 아게 이노시톨 포스페이트 올리고(에틸렌 글리콜) 화합물의임상 투여 일정
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5444901A (en) * 1977-09-12 1979-04-09 Ricoh Kk Treating liquid for flat printing plate
SE8605063D0 (sv) * 1986-11-26 1986-11-26 Matti Siren Derivatives of cyclohexane
GB8705811D0 (en) * 1987-03-11 1987-04-15 Research Corp Ltd Inositol derivatives
JP5345532B2 (ja) * 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Ｌｃｔ中毒に対する医薬品
DE102006062250A1 (de) * 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
US8809392B2 (en) * 2008-03-28 2014-08-19 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
WO2010049921A1 (en) * 2008-10-31 2010-05-06 Alimentary Health Limited Disaccharides
WO2012138963A1 (en) * 2011-04-06 2012-10-11 The Board Of Regents Of The University Of Texas System Inositol hexakisphosphate analogs and uses thereof

Also Published As

Publication number Publication date
AU2017202419B2 (en) 2017-08-31
CN105949234B (zh) 2018-07-10
EP3521294A1 (en) 2019-08-07
NZ624189A (en) 2015-05-29
CA2849426A1 (en) 2013-04-04
MX2014003771A (es) 2015-03-20
US9358243B2 (en) 2016-06-07
IL231698A (en) 2017-06-29
AU2012314932B2 (en) 2017-01-19
ES2727633T3 (es) 2019-10-17
AU2017202419A1 (en) 2017-05-11
PL2773648T3 (pl) 2020-03-31
EP2773648A1 (en) 2014-09-10
JP5766884B2 (ja) 2015-08-19
US20140235590A1 (en) 2014-08-21
BR112014007405A2 (pt) 2017-04-04
EP2773648B1 (en) 2019-03-13
EA024069B1 (ru) 2016-08-31
WO2013045107A1 (en) 2013-04-04
JP2014532049A (ja) 2014-12-04
CN105949234A (zh) 2016-09-21
BR112014007405B1 (pt) 2021-07-13
DK2773648T3 (da) 2019-05-20
CA2849426C (en) 2020-03-24
CN103958535A (zh) 2014-07-30
EA201490726A1 (ru) 2014-08-29
AU2012314932A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
MX2014003771A (es) Compuestos farmaceuticos para usarse en la terapia de infeccion por clostridium difficile.
CA2875877C (en) Syk inhibitors
NZ627274A (en) Anesthetic compounds and related methods of use
MX351581B (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
NZ739248A (en) Inhibitors of hepatitis c virus
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
BR112012022125A2 (pt) composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
MY163202A (en) Indolizine derivatives, proces for the preparation thereof and therapeutic use thereof
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
MX2014000626A (es) Nuevos derivados de indol sustituidos como moduladores de gamma secretasa.
PH12016502037A1 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
MX2016006336A (es) Compuestos pirazolopirimidina.
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
MX2017000330A (es) Derivado de piridona que tiene un grupo tetrahidropiranilmetilo.
IN2014DN07509A (es)
MY170262A (en) Dicarboxylic acid compound
NZ612920A (en) Process of making gyrase and topoisomerase iv inhibitors
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics
MX2015017864A (es) Metodo de preparacion de derivados de acido pirrolidina-2-carboxil ico.
MX2015002705A (es) Compuestos de piridinona para usarse en terapia fotodinamica.
UA116877C2 (uk) Сполука з антибактеріальною і/абопротивірусною активністю
MY162537A (en) dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds
PH12015502060A1 (en) Hydrochloride salts of an antibiotic compound
UA102950C2 (ru) Азабицикло[3.1.0]гекс-2-иловые соединения, способ их получения и фармацевтическая композиция, которая их содержит
UA111150C2 (uk) Гетероциклічна сполука як інгібітор циклу поділу клітини 7, лікарський засіб, що її містить, її застосування та спосіб інгібування циклу клітинного поділу 7 та профілактики або лікування раку у ссавця

Legal Events

Date Code Title Description
FG Grant or registration